Our key contribution is to discover and develop safe, innovative
biological medicines and make them accessible to reach our goal of
improving access to care. We work towards a future where all people
living with hemophilia, with or without inhibitors, have the
opportunity to live the life they desire.
Changing Hemophilia® represents Novo Nordisk’s commitment to the hemophilia community by connecting the company’s activities, development of new treatments to support of community projects aimed at improving the lives of people with hemophilia.